Why the study?
The impact of systemic inflammation on long-term functional prognosis in hypertensive COVID-19 survivors, particularly those at intermediate risk on the HFA-PEFF scale, remains inadequately explored.
Population
200 COVID-19 survivors with hypertension
Comparison
Stratified according to the HFA-PEFF scale
Follow-up
12-month
Key result
Among COVID-19 survivors with hypertension, those with an HFA-PEFF score ≥2 (62%) exhibited persistent subclinical inflammation, insulin resistance, and myocardial remodeling at 12 months.
Authors
Loading...
COVID-19 survivors with hypertension and an intermediate HFA-PEFF score (≥2) exhibit persistent subclinical inflammation, insulin resistance, and myocardial remodeling, suggesting a higher risk for developing HFpEF.
Cohort (n=200)
COVID-19 survivors with hypertension and an intermediate HFA-PEFF score (≥2) exhibit persistent subclinical inflammation, insulin resistance, and myocardial remodeling, suggesting a higher risk for developing HFpEF.
Avdeeva et al. (2026) conducted a cohort in COVID-19 survivors with hypertension (n=200). HFA-PEFF score ≥2 vs. HFA-PEFF score <2 was evaluated on Metabolic, inflammatory, and echocardiographic metrics. Among COVID-19 survivors with hypertension, those with an HFA-PEFF score ≥2 (62%) exhibited persistent subclinical inflammation, insulin resistance, and myocardial remodeling at 12 months.